Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis

Abstract

Background We aimed to identify the perception of physicians on the limitations and delays for diagnosing, staging and treatment of lung cancer in Portugal. Methods Portuguese physicians were invited to participate an electronic survey (Feb-Apr-2020). Descriptive statistical analyses were performed, with categorical variables reported as absolute and relative frequencies, and continuous variables with non-normal distribution as median and interquartile range (IQR). The association between categorical variables was assessed through Pearson’s chi-square test. Mann-Whitney test was used to compare categorical and continuous variables (Stata v.15.0). Results Sixty-one physicians participated in the study (45 pulmonologists, 16 oncologists), with n = 26 exclusively assisting lung cancer patients. Most experts work in public hospitals (90.16%) in Lisbon (36.07%). During the last semester of 2019, responders performed a median of 85 (IQR 55–140) diagnoses of lung cancer. Factors preventing faster referral to the specialty included poor articulation between services (60.0%) and patients low economic/cultural level (44.26%). Obtaining National Drugs Authority authorization was one of the main reasons (75.41%) for delaying the begin of treatment. The cumulative lag-time from patients’ admission until treatment ranged from 42–61 days. Experts believe that the time to diagnosis could be optimized in around 11.05 days [IQR 9.61–12.50]. Most physicians (88.52%) started treatment before biomarkers results motivated by performance status deterioration (65.57%) or high tumor burden (52.46%). Clinicians exclusively assisting lung cancer cases reported fewer delays for obtaining authorization for biomarkers analysis (p = 0.023). Higher waiting times for surgery (p = 0.001), radiotherapy (p = 0.004), immunotherapy (p = 0.003) were reported by professionals from public hospitals. Conclusions Physicians believe that is possible to reduce delays in all stages of lung cancer diagnosis with further efforts from multidisciplinary teams and hospital administration.

Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire

“…In most Portuguese institutions, the results take 14–21 days, 1 week longer than international guidelines recommend. These data are in agreement with another Portuguese study of lung cancer, which reported a median waiting time for the results of biomarker assays of 17.9 days [ 54 ]. Lim et al.…”

Delays in Diagnosis and Treatment in Patients Underwent Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA)

“…In a study of 1330 patients with lung cancer by Fernandez et al, the mean diagnosis time was found to be 19.8 ± 13.9 days [14]. In a recent survey analysis, the median time to diagnosis in cancer patients was found to be 11.05 days [15]. In our study, the diagnosis time and delay were found to be quite high compared to the literature, especially in malignant patients.…”

Impact of time-to-treatment initiation on survival in single primary non-small cell lung Cancer: A population-based study

“…Timely management standards for lung cancer have been established by some countries [ [18] , [19] , [20] , [21] , [22] ], but these standards are not well supported by evidence and are based mainly on expert consensus. Discrepancies exist between the recommendations and current practice.…”